JP2019537424A5 - - Google Patents

Download PDF

Info

Publication number
JP2019537424A5
JP2019537424A5 JP2019512267A JP2019512267A JP2019537424A5 JP 2019537424 A5 JP2019537424 A5 JP 2019537424A5 JP 2019512267 A JP2019512267 A JP 2019512267A JP 2019512267 A JP2019512267 A JP 2019512267A JP 2019537424 A5 JP2019537424 A5 JP 2019537424A5
Authority
JP
Japan
Prior art keywords
amino acid
protein
recombinant protein
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019512267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019537424A (ja
JP7183149B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/049894 external-priority patent/WO2018045308A1/en
Publication of JP2019537424A publication Critical patent/JP2019537424A/ja
Publication of JP2019537424A5 publication Critical patent/JP2019537424A5/ja
Priority to JP2022186724A priority Critical patent/JP7500692B2/ja
Application granted granted Critical
Publication of JP7183149B2 publication Critical patent/JP7183149B2/ja
Priority to JP2024091170A priority patent/JP2024123036A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019512267A 2016-09-02 2017-09-01 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用 Active JP7183149B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022186724A JP7500692B2 (ja) 2016-09-02 2022-11-22 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用
JP2024091170A JP2024123036A (ja) 2016-09-02 2024-06-05 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383267P 2016-09-02 2016-09-02
US62/383,267 2016-09-02
PCT/US2017/049894 WO2018045308A1 (en) 2016-09-02 2017-09-01 Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022186724A Division JP7500692B2 (ja) 2016-09-02 2022-11-22 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用

Publications (3)

Publication Number Publication Date
JP2019537424A JP2019537424A (ja) 2019-12-26
JP2019537424A5 true JP2019537424A5 (OSRAM) 2020-09-17
JP7183149B2 JP7183149B2 (ja) 2022-12-05

Family

ID=59887401

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019512267A Active JP7183149B2 (ja) 2016-09-02 2017-09-01 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用
JP2022186724A Active JP7500692B2 (ja) 2016-09-02 2022-11-22 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用
JP2024091170A Pending JP2024123036A (ja) 2016-09-02 2024-06-05 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022186724A Active JP7500692B2 (ja) 2016-09-02 2022-11-22 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用
JP2024091170A Pending JP2024123036A (ja) 2016-09-02 2024-06-05 安定化されたグループ2インフルエンザヘマグルチニンステム領域三量体およびその使用

Country Status (11)

Country Link
US (3) US11338033B2 (OSRAM)
EP (1) EP3506938A1 (OSRAM)
JP (3) JP7183149B2 (OSRAM)
KR (2) KR20190056382A (OSRAM)
CN (2) CN118146389A (OSRAM)
AU (2) AU2017321883B2 (OSRAM)
BR (1) BR112019004189A2 (OSRAM)
CA (1) CA3035443A1 (OSRAM)
IL (3) IL315821A (OSRAM)
SG (2) SG10201912944QA (OSRAM)
WO (1) WO2018045308A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3054971B1 (en) 2013-10-11 2021-03-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
EP3506938A1 (en) * 2016-09-02 2019-07-10 The U.S.A. as represented by the Secretary, Department of Health and Human Services Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
GB2578163A (en) * 2018-10-19 2020-04-22 Univ Pretoria Plant produced avian influenza antigens and their uses in diagnostic assays and devices
EP3921332A2 (en) 2019-02-08 2021-12-15 The USA, as represented by The Secretary, Department of Health and Human Services Nanoparticle-based influenza virus vaccines and uses thereof
EP4110384A4 (en) * 2020-02-26 2024-07-31 The Wistar Institute of Anatomy and Biology COMPOSITIONS CONTAINING SELF-ASSEMBLING VACCINES AND METHODS OF USE THEREOF
CN111560074B (zh) * 2020-03-20 2021-07-09 中山大学 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
WO2022200575A1 (en) 2021-03-26 2022-09-29 Glaxosmithkline Biologicals Sa Immunogenic compositions
EP4313137A1 (en) 2021-03-26 2024-02-07 GlaxoSmithKline Biologicals SA Immunogenic compositions
WO2023274860A1 (en) 2021-06-28 2023-01-05 Glaxosmithkline Biologicals Sa Novel influenza antigens
CA3232599A1 (en) 2021-09-16 2023-03-23 Emergent Product Development Gaithersburg Inc. Vaccine compositions
WO2023061993A1 (en) 2021-10-13 2023-04-20 Glaxosmithkline Biologicals Sa Polypeptides
GB202219228D0 (en) 2022-12-20 2023-02-01 Glaxosmithkline Biologicals Sa Novel influenza antigens
WO2024131862A1 (zh) * 2022-12-22 2024-06-27 北京吉诺卫生物科技有限公司 一种rsv疫苗及其制备方法与应用
CN115850396B (zh) * 2022-12-22 2024-02-06 北京吉诺卫生物科技有限公司 一种rsv纳米颗粒疫苗及其制备方法与应用
WO2024163912A2 (en) * 2023-02-03 2024-08-08 The Children's Medical Center Corporation Vaccine and therapeutic protein delivery compositions comprising fusion proteins
WO2024167855A1 (en) 2023-02-06 2024-08-15 Emergent Product Development Gaithersburg Inc. Influenza hemagglutinin constructs and compositions
WO2024197134A1 (en) * 2023-03-21 2024-09-26 President And Fellows Of Harvard College Coronavirus spike protein-based vaccines

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337070B1 (en) 1993-04-29 2002-01-08 Takara Shuzo Co., Ltd. Polypeptides for use in generating anti-human influenza virus antibodies
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
CA2776391C (en) 2001-10-01 2015-03-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Development of a preventive vaccine for filovirus infection in primates
US20050108791A1 (en) 2001-12-04 2005-05-19 Edgerton Michael D. Transgenic plants with improved phenotypes
CA2485363C (en) 2002-05-10 2014-10-28 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
EP1532167B1 (en) 2002-07-17 2012-01-25 Cytos Biotechnology AG Molecular antigen arrays using a virus like particle derived from the ap205 coat protein
US20060130158A1 (en) 2002-08-30 2006-06-15 Turner Andrew J Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
US7566458B2 (en) 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
GB0319797D0 (en) 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
US7897408B2 (en) 2005-09-12 2011-03-01 Japan Science And Technology Agency Method for producing CdS-apoferritin and ZnS-apoferritin complexes
US20070224205A1 (en) 2006-03-07 2007-09-27 Powell Thomas J Compositions that include hemagglutinin, methods of making and methods of use thereof
EP2111233A2 (en) 2006-12-29 2009-10-28 Institut Pasteur Of Shanghai Lentivirus pseudotyped with influenza hemagglutinin and methods of use
MX2009013008A (es) 2007-05-31 2010-06-09 Vacunas para la influenza.
US8778847B2 (en) 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
CN101820903A (zh) 2007-08-20 2010-09-01 美国弗劳恩霍夫股份有限公司 预防性和治疗性流感疫苗、抗原、组合物和方法
US8546337B2 (en) 2008-02-01 2013-10-01 Alpha-O-Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
JP5382489B2 (ja) 2008-03-29 2014-01-08 国立大学法人 奈良先端科学技術大学院大学 円偏光発光性ナノ微粒子
US20110177122A1 (en) 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
JP2012521786A (ja) 2009-03-30 2012-09-20 モウント シナイ スクール オフ メディシネ インフルエンザウイルスワクチン及びその使用
DK2480560T3 (en) 2009-09-22 2018-04-16 Medicago Inc PROCEDURE FOR THE PREPARATION OF PLANT DERIVATIVE PROTEINS
US20120219584A1 (en) 2009-10-05 2012-08-30 The United States Of America As Represented By The Secretary, Department Of Health Protection against pandemic and seasonal strains of influenza
US9352031B2 (en) 2010-02-18 2016-05-31 Technovax, Inc. Universal virus-like particle (VLP) influenza vaccines
CA2821492A1 (en) * 2010-12-13 2012-06-21 The University Of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
ES2953393T3 (es) 2011-09-20 2023-11-10 Icahn School Med Mount Sinai Vacunas contra el virus de la influenza y sus usos
US9441019B2 (en) * 2011-09-23 2016-09-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza hemagglutinin protein-based vaccines
SG11201402633UA (en) 2011-11-28 2014-09-26 Crucell Holland Bv Influenza virus vaccines and uses thereof
WO2013177444A2 (en) 2012-05-23 2013-11-28 The Board Of Trustees Of The Leland Stanford Junior University Influenza vaccine constructs
EP2934581B1 (en) * 2012-12-18 2022-09-14 Icahn School of Medicine at Mount Sinai Influenza virus vaccines and uses thereof
CA2913859C (en) 2013-05-30 2021-11-30 Crucell Holland B.V. Influenza virus vaccines and uses thereof
EP3054971B1 (en) 2013-10-11 2021-03-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
CN111500631B (zh) * 2013-10-28 2024-03-29 蓝天免疫疗法有限责任公司 用于病毒疗法的新型流感病毒载体
CA2950085A1 (en) 2014-05-27 2015-12-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Stabilized influenza hemagglutinin stem region trimers and uses thereof
SG11201610456UA (en) 2014-07-10 2017-01-27 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
TWI720946B (zh) 2014-08-08 2021-03-11 美商Vlp醫療股份有限公司 包含改質套膜蛋白質e3之類病毒粒子
SG11201705264WA (en) 2014-12-31 2017-07-28 The Usa As Represented By The Secretary Detp Of Health And Human Services Novel multivalent nanoparticle-based vaccines
EP3474893A1 (en) * 2016-06-27 2019-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
EP3506938A1 (en) * 2016-09-02 2019-07-10 The U.S.A. as represented by the Secretary, Department of Health and Human Services Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
WO2021231729A1 (en) * 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza

Similar Documents

Publication Publication Date Title
JP2019537424A5 (OSRAM)
JP2023018073A5 (OSRAM)
US11793871B2 (en) Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
ES2839880T3 (es) Vacuna contra el VRS
TWI874544B (zh) 變異型rsv f蛋白質及其利用
Ravin et al. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency
WO2012163289A1 (zh) 包含白喉毒素无毒突变体crm197或其片段的融合蛋白
KR102777000B1 (ko) 인플루엔자 바이러스 백신 및 이의 용도
CN105452270A (zh) 流行性感冒病毒疫苗及其用途
JP2015509707A5 (OSRAM)
JP2018531578A5 (OSRAM)
US20160000901A1 (en) Compositions and Methods for the Production of Virus-Like Particles
CN107344969A (zh) 一种纳米流感疫苗及构建方法和应用
CN111556896A (zh) 交叉免疫抗原疫苗及其制备方法
JP7545955B2 (ja) インフルエンザhaスプリットワクチンの製造方法
WO2018175560A1 (en) Nanoparticle immunogens to elicit responses against the influenza receptor binding site on the hemagglutinin head domain
CN110201183A (zh) 一种可同时递送抗原和免疫增强剂的纳米制剂
WO2020246584A1 (ja) ペプチド核酸を基盤としたアジュバント
Zhu et al. Protection against the H1N1 influenza virus using self-assembled nanoparticles formed by lumazine synthase and bearing the M2e peptide
CN106337038B (zh) 一种通过转肽酶剪切制备疫苗的方法及其应用
Kotlyarov et al. Development of recombinant vaccine against A (H1N1) 2009 influenza based on virus-like nanoparticles carrying the extracellular domain of M2 protein
CN103242426B (zh) 禽流感病毒h5n1亚型限制性ctl表位多肽及其应用
WO2024199469A1 (zh) 具有稳定融合前构象的呼吸道合胞病毒f蛋白